CEO: Ashanthi Mathai

Visit Website

The opioid crisis continues to ravage the United States, with an estimated 50,000 Americans dying each year to opioid overdoses. While Naloxone reverses the over-sedation and cessation of breathing caused by opioid overdosage, access barriers such a high cost, the need for prescription to claim insurance, lingering social stigmatization, and limited rural availability too often prevent those who need it the most from acquiring it. Consequently, Pocket Naloxone is developing an over-the-counter, opioid overdose rescue medication that will cost significantly less than what’s currently available to meet this access need.